Aptevo Therapeutics Inc.
APVO· Nasdaq
APVOAptevo Therapeutics Inc.
Who holds Aptevo Therapeutics Inc., from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 12.7K | ±0% | $56.4K | 0% | Aug 13, 2026 |
| Geode Capital Management, LLC | 10.8K | −18.9% | $48K | 0% | Aug 12, 2026 |
| Vanguard Fiduciary Trust Co | 4.1K | ±0% | $18.4K | 0% | Aug 13, 2026 |
| UBS Group AG | 730 | −78.8% | $3.2K | 0% | Aug 13, 2026 |
| Osaic Holdings, Inc. | 360 | ±0% | $1.6K | 0% | Aug 14, 2026 |
| SBI Securities Co., Ltd. | 109 | ±0% | $484 | 0% | Jul 23, 2026 |
| Barclays PLC | 31 | New | $138 | 0% | Aug 14, 2026 |
| GSA Capital Partners LLP | 21.5K | +9.7% | $96 | 0.1% | Aug 6, 2026 |
| Danske Bank A/S | 1 | ±0% | $4 | 0% | Aug 10, 2026 |
